X hits on this document

Powerpoint document

PRIMARY AND SECONDARY PREVENTION OF CARDIOVASCULAR DISEASES - page 26 / 38

99 views

0 shares

0 downloads

0 comments

26 / 38

ACE-I’s and ARB’s-Class 1

Benefits of ACE-I is large after MI

7% mortality reduction at 30 days with normal LVEF

26% mortality reduction at 30 days with low LVEF

HOPE Trial demonstrated 22% reduction in major clinical events in low risk patients without CVD, DM or CHF

CHARM-Use of candesartin in patients with CHF prevents

1 death per 63 patients treated

1 hospitalization per 23 patients treated

1 new case of DM per 71 patients treated

Document info
Document views99
Page views99
Page last viewedThu Dec 08 21:00:44 UTC 2016
Pages38
Paragraphs624
Words2577

Comments